https://investors.endrainc.com/
ENDRA’s first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
Their 501(K) FDA results should be coming soon (though there’s always the risk it’ll be declined). Already approved in some euro countries.